Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors

Alnylam Pharmaceuticals reported robust Q2 performance, with TTR revenue reaching $544 million (77% YoY growth), significantly boosted by the faster-than-expected U.S. launch of its ATTR cardiomyopathy treatment, contributing $150 million from 1,400 patients. The company raised its 2025 TTR revenue guidance by over 30% to $2.175-$2.275 billion and is on the cusp of non-GAAP profitability. Future growth is underpinned by its third-generation TTR product, nucrisiran (expected 2028/2030 launch with extended IP and improved economics), and the hypertension drug zilebesiran (Phase III underway, targeting 2030 launch with Roche), showcasing the platform's serial innovation capability and a diversified long-term strategy.

Analysis

Alnylam Pharmaceuticals has demonstrated exceptional execution in its TTR franchise, reporting Q2 revenue of $544 million, a 77% year-over-year increase. This growth was overwhelmingly driven by the U.S. launch into the cardiomyopathy (CM) market, which contributed an estimated $150 million from approximately 1,400 patients in its inaugural quarter. The launch velocity significantly surpassed initial expectations, primarily due to an accelerated provider setup and formulary adoption at key health systems, a process that was nearly completed in one quarter rather than the projected 6-9 months. Consequently, Alnylam raised its full-year 2025 TTR revenue guidance by over 30% to a range of $2.175 billion to $2.275 billion, signaling confidence in sustained momentum from both first-line and second-line demand. The company is now on the verge of achieving non-GAAP profitability, a key financial goal. Looking forward, the pipeline holds significant long-term value drivers, most notably Nucrisiran, a third-generation TTR product that promises a superior financial profile by eliminating a heavy 15-30% royalty burden on Amvuttra and extending patent protection into the 2040s. Additionally, the hypertension program, Zilebesiran, partnered with Roche, represents a major diversification opportunity and potential 'second act' for growth into the 2030s.

Key Decisions for Investors

• Given the substantial TTR guidance raise was based on only one quarter of CM launch data, investors should model for potential upside, closely monitoring sequential revenue growth in the second half of the year against the implied forecast.
• The strategic value of the pipeline, particularly the third-generation TTR asset Nucrisiran, should be a core part of any long-term thesis, as its royalty-free structure presents a significant future margin expansion opportunity and extends the franchise's durability beyond the TAF generic entry in 2028.
• While the U.S. launch is a clear success, monitor the ex-U.S. expansion, which is expected to have a more gradual ramp due to pricing negotiations, and track competitive data from the Ionis/AstraZeneca silencer expected in H2 2026.
• As Alnylam transitions to profitability, focus should shift to the company's capital allocation strategy and its ability to translate top-line growth into meaningful operating margin expansion and shareholder returns.